The Potential of Cardiac Biomarkers in Differentiating Disease Subtypes in Patients with Systemic Sclerosis: Focus on GDF15, MR-pro ANP, and suPAR
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26093938 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Olga Gumkowska-Sroka und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine Rheumatology and Clinical Immunology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, 40-635 …. Hauptthemen laut MEDLINE: Growth Differentiation Factor 15, Biomarkers, Atrial Natriuretic Factor, Scleroderma, Systemic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Silesia, Katowice, Poland, Medical University of Silesia Poland.
Abstract (Originalsprache)
Systemic sclerosis, a connective tissue disease of unknown etiology and unpredictable outcomes, is characterized by the fibrosis of the skin and internal organs, vasculopathy, and immune system dysregulation. The disease is classified into two main subtypes, which differ in clinical presentation, complications, and prognosis. While several biomarkers have been proposed to distinguish between these subtypes, none have achieved high sensitivity and specificity. The search for dependable markers that can differentiate between the two primary subtypes of systemic sclerosis continues. To address this gap, our study evaluated the utility of novel cardiac biomarkers, including growth differentiation factor 15 (GDF15), galectin-3, mid-regional pro-atrial natriuretic peptide (MR-proANP), glutathione S-transferase π, mid-regional adrenomedullin, and soluble urokinase plasminogen activator receptor (suPAR), in a cohort of 79 patients with both lcSSc and dSSc subtypes. The results demonstrated a significant elevation of GDF15 (medians: 2.07 vs. 1.10 ng/L; p < 0.001) and MR-proANP (92.55 vs. 65.60 pmol/L; p < 0.05) levels in SSc patients compared to healthy controls. Moreover, GDF15 (1.65 vs. 2.34 ng/mL; p < 0.05), MR-proANP (80.87 vs. 109.27 pmol/L; p < 0.05), and suPAR (1.83 vs. 2.44 ng/mL; p < 0.05) levels were notably higher in patients with dSSc compared to those with lcSSc. In the ROC analysis, only GDF-15, MR-proANP, and suPAR proved to have a statistically significant area under the curve (AUC). Patients with the GDF-15 ≥ 2182 ng/mL, MR-prANP ≥ 85.808 pmol/L, and suPAR ≥ 2.315 ng/mL have more than six-, eight-, and seven-times-higher odds for dcSSc, respectively. These findings highlight the potential of GDF15, suPAR, and MR-proANP as biomarkers for differentiating between the two main subtypes of systemic sclerosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine Rheumatology and Clinical Immunology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, 40-635 Katowice, Poland.
- Department of Rheumatology and Clinical Immunology, Voivodeship Hospital, No. 5, 41-200 Sosnowiec, Poland.
- Health Promotion and Obesity Management Unit, Department of Pathophysiology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, 40-752 Katowice, Poland.
- Department of Clinical Chemistry and Laboratory Diagnostics, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, 41-200 Katowice, Poland.
- Department of Internal Medicine and Oncological Chemotherapy, Medical University of Silesia, 40-029 Katowice, Poland.
ORCID-Profile: Anna Chudek, Kornelia Kuźnik-Trocha, Jerzy Chudek, Katarzyna Komosińska-Vassev, Katarzyna Winsz-Szczotka, Krystyna Olczyk, Przemysław Kotyla
Förderung
- Medical University of Silesia, Katowice, Poland
- Medical University of Silesia Poland
Zitieren
APA
Gumkowska-Sroka, O., Chudek, A., Owczarek, A., Kuźnik-Trocha, K., Kotyla, K., Kurdybacha, J., Chudek, J., Komosińska-Vassev, K., Winsz-Szczotka, K., Olczyk, K., & Kotyla, P. (2025). The Potential of Cardiac Biomarkers in Differentiating Disease Subtypes in Patients with Systemic Sclerosis: Focus on GDF15, MR-pro ANP, and suPAR. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26093938
Vancouver
Gumkowska-Sroka O, Chudek A, Owczarek A, Kuźnik-Trocha K, Kotyla K, Kurdybacha J, et al. The Potential of Cardiac Biomarkers in Differentiating Disease Subtypes in Patients with Systemic Sclerosis: Focus on GDF15, MR-pro ANP, and suPAR. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26093938
BibTeX
@article{GumkowskaSroka2025,
author = {Gumkowska-Sroka, Olga and Chudek, Anna and Owczarek, Aleksander and Kuźnik-Trocha, Kornelia and Kotyla, Kacper and Kurdybacha, Jan and Chudek, Jerzy and Komosińska-Vassev, Katarzyna and Winsz-Szczotka, Katarzyna and Olczyk, Krystyna and Kotyla, Przemysław},
title = {The Potential of Cardiac Biomarkers in Differentiating Disease Subtypes in Patients with Systemic Sclerosis: Focus on GDF15, MR-pro ANP, and suPAR},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26093938}
}
EUVIMED